SK Bioscience acquires $3m stake in US biotech firm
South Korean biotech firm SK Bioscience said Tuesday it has invested $3 million in the US-based biotech firm Fina Biosolutions to acquire a stake in the company as part of the company’s broader strategy to secure next-generation vaccine technologies and enhance its global competitiveness in the vaccine market. Founded in 2006, Fina Biosolutions specializes in conjugate vaccines widely used in vaccines to prevent illnesses such as pneumonia, meningococcal disease and typhoid. The company is
Oct. 8, 2024